Form 4: Ocuphire Pharma Executive Acquires 2,000 Shares of Common Stock
SEC Form 4 Filing
Joseph K. Schachle, Chief Operating Officer of Ocuphire Pharma, Inc., recently purchased 2,000 shares of the company's common stock at a price of $2.05 per share.
Summary
- On March 21, 2024, Joseph K. Schachle, the Chief Operating Officer of Ocuphire Pharma, Inc., acquired 2,000 shares of common stock.
- The purchase price was $2.05 per share.
- Following the transaction, Mr. Schachle directly owns 2,000 shares of Ocuphire Pharma, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. An insider purchase is generally viewed favorably, but the small size of the transaction limits the impact.
Positives
- The purchase of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's sentiment towards the company's prospects. It can be a positive signal, but should be considered in conjunction with other factors.
Stakeholder Impact
- The transaction could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 2024-02-01 | Date of Power of Attorney execution. |
| 2024-03-21 | Date of common stock transaction. |
| 2024-03-25 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.